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ABSTRACT The amyloid precursor protein (APP) is the precursor of the -amyloid peptide (A), which is centrally related
to the genesis of Alzheimer’s disease (AD). In addition, APP has been suggested to mediate and/or participate in events that
lead to neuronal degeneration in AD. Despite the fact that various aspects of the cell biology of APP have been investigated,
little information on the structure of this protein is available. In this work, the solution structure of the soluble extracellular
domain of APP (sAPP, composing 89% of the amino acid residues of the whole protein) has been investigated through a
combination of size-exclusion chromatography, circular dichroism, and synchrotron radiation small-angle x-ray scattering
(SAXS) studies. sAPP is monomeric in solution (65 kDa obtained from SAXS measurements) and exhibits an anisometric
molecular shape, with a Stokes radius of 39 or 51 Å calculated from SAXS or chromatographic data, respectively. The radius
of gyration and the maximum molecular length obtained by SAXS were 38 Å and 130 Å, respectively. Analysis of SAXS data
further allowed building a structural model for sAPP in solution. Circular dichroism data and secondary structure predictions
based on the amino acid sequence of APP suggested that a significant fraction of APP (30% of the amino acid residues) is
not involved in standard secondary structure elements, which may explain the elongated shape of the molecule recovered in
our structural model. Possible implications of the structure of APP in ligand binding and molecular recognition events involved
in the biological functions of this protein are discussed.
INTRODUCTION
The amyloid precursor protein (APP) is genetically and
biochemically linked to the genesis of Alzheimer’s disease
(AD), the most widespread cause of dementia in industrial-
ized countries (De Strooper and Annaert, 2000). Human
APP is a ubiquitous transmembrane protein that spans the
plasma membrane a single time (Kang et al., 1987) and
exists in various alternatively spliced isoforms. The pre-
dominant non-neuronal isoforms, APP751 and APP770, con-
tain a Kunitz-type protease inhibitor domain (Kitaguchi et
al., 1988; Ponte et al., 1988; Tanzi et al., 1988; see Fig. 1).
This domain has been shown to be a modulator of the
blood-clotting cascade (Van Nostrand et al., 1990). The
predominant isoform in neurons, APP695, is a moderately
glycosylated isoform lacking the protease inhibitor domain
(De Strooper and Annaert, 2000). On its way to the plasma
membrane, APP undergoes (N  O)-glycosylation, ty-
rosine-sulfation (Weidemann et al., 1989), and phosphory-
lation (Caporaso et al., 1992).
The half-life of APP in the plasma membrane is10 min
(Koo et al., 1996). It is either cleaved extracellularly or
recycled to an intracellular compartment, apparently acidic
endosomal vesicles and lysosomes. Proteolytic cleavage of
APP can also occur intracellularly, resulting in a pool of
secreted APP (sAPP) contained in vesicles that are subject
to polarized traffic (Haass et al., 1994). Extracellular cleav-
age of APP occurs predominantly by action of -secretase
(Lammich et al., 1999), which cleaves APP at a site located
13 amino acid residues upstream from its membrane inser-
tion (Fig. 1). APP can also be cleaved by -secretase at the
-site, located 29 amino acid residues upstream from its
membrane insertion point (Hussain et al., 1999; Sinha et al.,
1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 1999).
The soluble extracellular fragments released upon cleavage
by both -secretase(s) (sAPP) and -secretase (sAPP)
can be detected in the extracellular medium (Seubert et al.,
1993). Further intramembranous cleavage by -secretase(s)
(Durkin et al., 1999) releases either p3 or the -amyloid
peptide, A, to intracellular vesicles or the extracellular
medium, and leaves a cytoplasmic stub that can migrate to
the nucleus and modulate gene expression (Kimberly et al.,
2001; Gao and Pimplikar, 2001; Fig. 1). A can aggregate
in the extracellular medium to form amyloid fibrils and the
senile plaques characteristically found in AD brains and
thought to be implicated in neuronal death in this disease
(Masters et al., 1985).
Research into the biochemistry and cell biology of
neuronal dysfunction and death in AD has mainly fo-
cused on A. However, considerable evidence indicates
that other domains of APP may be important for normal
neuronal function (Sisodia and Gallagher, 1998) and may
also be involved in the neuropathology of AD (Barger
and Harmon, 1997). Although several studies have con-
centrated on the cell biology of APP, it has not yet been
possible to fully understand how the in vitro biochemical
properties of this protein relate to its functions in a
Submitted January 5, 2002, and accepted for publication July 16, 2002.
Address reprint requests to Se´rgio T. Ferreira, Cidade Universitaria, Rio de
Janeiro RJ 21941-590, Brazil. Tel.: 55-21-270-5988; Fax: 55-21-270-8647;
E-mail: ferreira@bioqmed.ufrj.br.
© 2002 by the Biophysical Society
0006-3495/02/12/3513/12 $2.00
3513Biophysical Journal Volume 83 December 2002 3513–3524
cellular context (Van Nostrand et al., 1990; Multhaup et
al., 1996). Furthermore, few structural data on APP are
currently available. This clearly represents an obstacle to
understanding structure-function relationships of APP
and the events leading to its pathological proteolysis and
secretion.
The structure of the Kunitz-type protease inhibitor do-
main present in the major non-neuronal isoforms of APP
has been obtained by x-ray crystallography (Hynes et al.,
1990). Another fragment of known structure is the N-ter-
minal domain (Rossjohn et al., 1999; indicated as HBD1 in
Fig. 1), which shows a general similarity to other proteo-
glycan receptors. It has been proposed that the N-terminal
domain contains one of several binding sites for heparan
sulfate proteoglycans (Mok et al., 1997) and mediates their
effects on cell viability and growth. The N-terminal domain
is also thought to bind to fibulin-1 (Ohsawa et al., 2001).
Other known ligands of APP are zinc and copper ions,
which appear to bind to the cysteine-rich region near the
N-terminal domain (Bush et al., 1994; Hesse et al., 1994;
Fig. 1), and collagen and laminin, which are thought to bind
to the glycosylation domain (Beher et al., 1996; Narindra-
sorasak et al., 1992).
The soluble ectodomain of APP (sAPP) is much more
amenable to physicochemical studies (e.g., using spec-
troscopic and chromatographic techniques) than the in-
tact transmembrane protein, and appears to mediate sim-
ilar physiological roles (Saitoh et al., 1989; Breen et al.,
1991; Mattson et al., 1993). In the present work, we have
expressed recombinant sAPP isoforms in the methano-
lotrophic yeast Pichia pastoris (Henry et al., 1997). The
proteins were purified to homogeneity and their confor-
mations were analyzed by size-exclusion chromatogra-
phy (SEC), circular dichroism (CD), and small-angle
x-ray scattering (SAXS). SAXS is a well-established
technique for obtaining structural information on macro-
molecules in solution under close to physiological con-
ditions (Trewhella, 1997). Over the past few years, the
use of synchrotron radiation and new theoretical ap-
proaches have provided solution structural data at better
than 1.5 nm resolution using SAXS (Chaco´n et al., 1998;
Svergun, 1999, 2001). The results obtained with sAPP
show an elongated shape for the molecule, and are dis-
cussed in terms of possible structural correlations with
biological functions of the extracellular domain.
MATERIALS AND METHODS
Protein expression
The three strains of Pichia pastoris expressing sAPP695, sAPP751, and
sAPP770 (see Fig. 1) were kindly provided by Dr. R. Cappai (University
of Melbourne, Australia) and were grown at 30°C in YPD [1% (w/v) yeast
extract (Gibco, Carlsbad, CA), 2% (w/v) peptone (Gibco), 2% (w/v)
D-glucose (Sigma, St. Louis, MO)]. Expression of each of the recombinant
protein isoforms was induced during 48 h in BMMY [1% (w/v) yeast
extract, 2% (w/v) peptone, 1.34% (w/v) yeast nitrogen base without amino
acids (Sigma), 4  105 % biotin (Sigma), 2% methanol (Merck, Darmstadt,
Germany)] (Henry et al., 1997).
FIGURE 1 Domain structure and cleavage of APP. APP: the entire transmembrane protein, including the signal peptide (SP), numbered as in APP770.
The 56-residue KPI domain (1AAP.PDB, Hynes et al., 1990), which is present in APP751 and APP770, and the 19-residue Ox2 sequence (Ox), which is
present in APP770, are shown above their insertion sites. HBD1, HBD2: putative heparin-binding domains (HBD1 is equivalent to 1MWP.PDB, Rossjohn
et al., 1999). CuBD: copper-binding domain. ZnBD: putative zinc-binding domain. (DE)n: Asp- and Glu-rich region with two Tyr-phosphorylation (P) sites.
N-Glc: N-glycosylation sites. RC: predicted random coil region. TM: transmembrane domain. A: amyloidogenic sequence that reaches partially into the
transmembrane domain. Cleavage by -secretase at its N-terminus and -secretase at its C-terminus (not shown) gives rise to the A peptide. Cyt:
cytoplasmic domain of APP with a Tyr-phosphorylation site (P). Cleavage by -secretase releases the soluble sAPP fragment (numbered as in sAPP770),
carrying at its C-terminus part of the amyloidogenic sequence (bold). The membrane-bound C-terminal stub can be further cleaved by -secretase (not
shown) into the p3 peptide (bold) and the cytoplasmic domain (Cyt). The diagram shows that sAPP770 is equivalent to APP18–687 (670 amino acid
residues), while sAPP751 has 651 residues, and sAPP695 has 595 residues.
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Purification of sAPP
Purification was carried out using a modification of the method of Henry
et al. (1997). Yeast cultures (0.5–2 l) were centrifuged at 16.000  g for
10 min at 4°C and the supernatants were filtered (0.45 m, Whatman,
Springfield Mill, U.K.). From this point the protein was always kept on ice.
The supernatant was diluted with buffer A [20 mM imidazole, 5 mM
EDTA, 10 mg/l phenylmethylsulfonyl fluoride (PMSF), pH 5.5] to ionic
strength 0.2 and applied at a flow-rate of 7 ml/min onto a Q-Sepharose
column (HR 26–10, Pharmacia, Uppsala, Sweden) pre-equilibrated with 6
vol of buffer A. The column was washed with 20 vol of buffer B (buffer
A  250 mM NaCl) and the protein was eluted in 2-ml fractions of buffer
C (20 mM Tris-HCl, 1 M NaCl, 5 mM EDTA, 10 mg/l PMSF, pH 7.4).
Fractions with high absorption at 280 nm were pooled and desalted in
pre-packed Sephadex G-25 columns (Pharmacia). The desalted pool was
applied onto a 5-ml HiTrap heparin Sepharose column (Pharmacia) con-
nected to an HPLC system and pre-equilibrated with 50 mM Tris-HCl, pH
7.4. The column was washed until A280 had reached baseline, and the
protein was then eluted with a linear gradient of salt up to 1 M NaCl. Eluted
peaks were monitored by A280. The fractions in the sAPP peak were pooled
and desalted in 50 mM Tris-HCl, pH 7.4, concentrated using a Centri-
con-30 device (Amicon, Bedford, MA), and stored at 4°C. Aliquots from
the conditioned medium and all subsequent purification steps were ana-
lyzed by SDS-PAGE (Laemmli, 1970), and the identity of sAPP was
verified by Western blots using anti-APP monoclonal antibody 22C11
(Boehringer Mannheim, Mannheim, Germany).
Protein determination
The protein contents of purified and desalted sAPP samples were calcu-
lated using 280 nm 60,110 M1 cm1 for sAPP695 and 280 nm 70,455
M1 cm1 for sAPP751 and sAPP770. These coefficients were calculated
by adding up the extinctions of all tryptophan, tyrosine, and cystine
residues in sAPP (Trp  5500 M1 cm1, Tyr  1490 M1 cm1, and
Cys-Cys  125 M1 cm1; Pace et al., 1995). sAPP695 has 7 Trp, 14 Tyr,
and 12 Cys residues, whereas sAPP751 and sAPP770 have 8 Trp, 17 Tyr,
and 18 Cys residues.
Copper-reducing activity assay
Variable amounts of sAPP were diluted to 700 l in a solution containing
750 M neocuproin and 100 M CuCl2. sAPP samples and negative
controls not containing protein were incubated for 60 min at 37°C, and
absorption spectra were measured at regular time intervals. In the wave-
length region from 400 to 500 nm, the spectra of all sAPP-containing
samples contained a single peak at 454 nm. The concentration of reduced
copper ions was calculated from the absorption at 454 nm using the
absorption coefficient of the neocuproin-Cu(I) complex at 454 nm (454 
7200 M1 cm1; Proudfoot et al., 1997).
Circular dichroism
sAPP isoforms were diluted to a concentration of 0.1 mg/ml in 50 mM
Tris-Cl, pH 7.4. Spectra were measured on Jasco J-715 and J-810 spec-
tropolarimeters (pathlength 0.1 or 0.2 cm). Secondary structure contents
were calculated from CD data using the programs CONTINLL, SEL-
CON3, and CDSSTR contained in the CDPro package (Sreerama and
Woody, 2000). This package allows evaluation of the robustness of the
analysis by comparing the values obtained using the three different algo-
rithms, which use the same database of proteins with known three-dimen-
sional structure.
Secondary structure prediction
The amino acid sequence of sAPP770 was analyzed to predict possible
secondary structure elements using the programs NNPREDICT (Kneller et
al., 1990) and DPM, DSC, GOR4, HHNC, MLRC, PHD, Predator,
SIMPA96, and SOPM included in the NPS@ package (Combet et al.,
2000).
Size-exclusion chromatography
This was performed on a GPC-100 column (250  4.6 mm, 15,900
theoretical plates, Eichrom Technologies, Inc., Darien, IL) connected to an
HPLC apparatus (Shimadzu, Kyoto, Japan). GPC-100 is a silica-based
column and, according to manufacturer’s instructions, may only be used at
pH  7. The column was equilibrated and operated at 22°C in buffer
containing 50 mM Tris, 150 mM NaCl, pH 6.8. The sample volume was
100 l and the flow rate was 0.3 ml/min. Elution was monitored by
absorbance at 280 nm. The void volume retention time, t0, was 5.25 min
(measured by the elution of plasmid DNA) and the total volume retention
time, tT, was 11.17 min (measured by the elution of Trp-Gly-Gly). From
these values, the partition coefficient of a given protein, Kd, was calculated
as:
Kd  te 	 t0/tT 	 t0 (1)
te being the elution time of a given protein. The Kd values for four proteins
of known Stokes radii (ovalbumin, 3.05 nm; bovine serum albumin, 3.55
nm; apoferritin, 6.1 nm; thyroglobulin, 8.5 nm; Pharmacia Biotech) were
measured to construct the Porath plot according to the empirical relation
(Siegel and Monty, 1966):
Kd
1/3  a
 rStokes  b (2)
The Stokes radii of the three sAPP isoforms were then estimated from the
Porath plot by a linear least-squares fit. The concentrations of the three
sAPP isoforms varied between 0.06 M and 3 M in different chromato-
graphic runs without any changes in elution time. Very similar results were
obtained using a Laurent and Killander plot, according to the relation
(Siegel and Monty, 1966):
log Kd1/2  a
 rStokes  b (3)
The uncertainties in known Stokes radii and the variation in our measured
(Kd)1/3 values are both of the order of 1%, while the goodness of the linear
least-squares fit is given by r2  0.96 for both Porath and Laurent and
Killander plots.
SAXS measurements and data analysis
Small-angle x-ray scattering experiments were performed at the SAS
beamline at the Laborato´rio Nacional de Luz Sı´ncrotron (LNLS) in Campi-
nas, Brazil (Kellermann et al., 1997). The monochromatic beam was tuned
at 8.33 keV. The experimental setup included a temperature-controlled,
1-mm-thick sample cell with mica windows and a linear position-sensitive
detector. Solutions of purified sAPP695 used in the SAXS measurements
had a maximum concentration of 2.6 mg/ml. The buffer solution used was
50 mM Tris, pH 7.4. The samples were kept at 10°C during the exposures.
A second (more diluted) protein sample (1.3 mg/ml) was also measured to
investigate possible concentration effects in the SAXS curves. Data acqui-
sition was performed by taking ten 900-s frames for each sample, which
allowed control of any possible radiation damage. Several sample-detector
distances enabled detection in the q range accessible within the given
experimental conditions: 0.02043 Å1  q  0.2997 Å1. Data treatment
was performed using the software package TRAT-1D (Oliveira et al.,
1997). Usual corrections for detector homogeneity, incident beam inten-
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sity, sample absorption, and blank subtraction were included in this routine.
The output of this software provides the corrected intensities and error
values. Data analysis was performed using GNOM (Svergun and Stuhr-
mann, 1991), SASHA (Svergun et al., 1996), DAMMIN (Svergun, 1999),
and HYDRO (Garcia de la Torre, 1999) software packages.
RESULTS
Purification and expression of sAPP
To obtain purified human sAPP in the amounts required
for biophysical measurements, recombinant isoforms
sAPP695, sAPP751, and sAPP770 were individually ex-
pressed in Pichia pastoris, which secreted sAPP into the
culture medium. SDS-PAGE analysis showed that, after
induction, the conditioned medium contained a predominant
protein band of the expected 	75 kDa for sAPP (Fig. 2 A,
lanes 1 and 2). After the first purification step on an ion-
exchange column, the protein-containing fractions were
highly concentrated and enriched in sAPP (Fig. 2 A, lane
3). From a heparin-affinity column, the peaks containing
full-length sAPP isoforms eluted at 	0.50 M NaCl, indi-
cating a high affinity for heparin. Each of those peaks
consisted of a single protein band (Fig. 2 A, lanes 4–6),
which reacted strongly with anti-APP antibody in Western
blots (Fig. 2 B, lanes 1 and 2).
Structural and functional integrity of
recombinant sAPP
Before proceeding with the structural characterization of
sAPP, it was important to ascertain that the purified re-
combinant proteins we used retained their expected biolog-
ical activities. The expression system in P. pastoris was
chosen because of the well-known ability of this eukaryote
host to glycosylate and phosphorylate secreted proteins
(Henry et al., 1997). P. pastoris has been reported to hy-
perglycosylate recombinant proteins less frequently than
Saccharomyces cerevisiae does (Henry et al., 1997). The
following lines of evidence indicated the structural and
functional integrity of sAPP. The high-affinity interaction
between APP and heparin has been extensively investigated
and associated with at least five different domains within
sAPP (Mok et al., 1997; Barger and Basile, 2001). Thus,
the fact that recombinant sAPP was strongly bound to
heparin-Sepharose (Fig. 2 A, lanes 4–6) indicates structural
preservation of the glycosaminoglycan-binding domains of
APP. In addition, APP specifically catalyzes the reduction
of copper (Multhaup et al., 1996), which is its only enzy-
matic activity known to date. This activity has been ascribed
to a sequence in the N-terminal half of sAPP (Multhaup et
al., 1996; Fig. 1). We have investigated the capacity of the
three purified sAPP isoforms to catalyze the reduction of
Cu(II) to Cu(I) using an assay based on the formation of a
Cu(I)-neocuproin complex (Proudfoot et al., 1997). Upon
incubation at 37°C, copper reduction catalyzed by APP was
linear up to 60 min of incubation (Fig. 3 A), and the specific
enzymatic rate thus calculated (0.24 mol Cu(I) formed per
minute per mol sAPP for all three isoforms) compares
quite favorably to previously reported activities (Multhaup
et al., 1996). Taken together, these results indicate that
recombinant sAPP retains the biological activities ex-
pected for genuine APP.
Circular dichroism
The far-UV CD spectra of the three sAPP isoforms at
22°C (Fig. 3 B) were very similar to that reported for
soluble APP directly purified from porcine brain (De La
Fournie`re-Bessoueille et al., 1997) and did not exhibit sig-
nificant changes in the temperature range between 10 and
30°C or between pH 6.8 and pH 7.4 (data not shown).
Analysis of the CD spectra yielded a secondary structure
content of 35–36% -helix, 13–16% -sheet, and 20–21%
-turn for the three sAPP isoforms, according to the three
different algorithms implemented in the CDPro package
(Sreerama and Woody, 2000). This indicates that a high
percentage (30%) of the amino acid residues in sAPP are
not involved in standard secondary structure elements in
this protein.
Hydrodynamic radius of sAPP
Size-exclusion chromatography experiments revealed that
the three isoforms of sAPP eluted at the same elution
volume under physiological buffer conditions (Fig. 4 A).
The elution volume of sAPP on a calibrated GPC-100
column corresponded to a Stokes radius of 51 Å (Fig. 4 B).
FIGURE 2 SDS-PAGE analysis of expressed and purified sAPP iso-
forms. (A) The gel (7.0% acrylamide) was stained with Coomassie Brilliant
Blue R. Lane 1: supernatant of yeast culture before induction; lane 2:
supernatant of recombinant sAPP695-expressing yeast culture after induc-
tion; lane 3: pooled, desalted preparation of sAPP695 after elution from
the Q-Sepharose column; lane 4: purified sAPP695 fraction eluted from
the heparin-Sepharose column; lane 5: purified sAPP751 fraction; lane 6:
purified sAPP770 fraction; 35 l of sample were applied in lanes 1–3;
17.5 l in lanes 5 and 6; 2 l (3 g of protein) were applied in lane 4 (this
sample had been concentrated on Centricon-10). (B) Western blot of a
7.0% acrylamide gel. The antibody used was 22C11. Lane 1: purified
sAPP695; lane 2: purified sAPP770.
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The elution profile of sAPP751 presented a minor shoulder
at lower elution volume, which could correspond to a small
fraction of dimers or higher order oligomers in the sample.
SAXS measurements and data analysis
Small-angle x-ray scattering by sAPP695 was measured
using synchrotron radiation. The choice of this isoform is
justified by the fact that it is predominant in neurons, and
therefore of special interest in the elucidation of the patho-
genesis of Alzheimer’s disease. Furthermore, the secondary
structure contents and the hydrodynamic radii of the three
isoforms were shown to be the same within experimental
error (see above), indicating that the three isoforms possess
similar structures. The corrected experimental intensity data
as a function of the modulus of the scattering vector q (q 
(4/) sin , where  is the wavelength used and 2 is the
scattering angle) is shown in Fig. 5 A. A Guinier plot of the
data (Guinier and Fournet, 1955) exhibited a linear region,
indicating satisfactory monodispersity of the protein sample
(Fig. 5 A, inset). The radius of gyration estimated using the
Guinier approximation was Rg  35 Å. There was no
FIGURE 3 (A) Copper-reducing activity of sAPP. Samples containing 100 M CuCl2, 750 M neocuproin and various concentrations of sAPP
isoforms were incubated at 37°C and the concentration of Cu(I) as calculated from the absorption of the neocuproin-Cu(I) complex at 454 nm measured
every 15 min. Buffer was 50 mM Tris-Cl, 50 mM NaCl, pH 7.4. Circles and solid line: sAPP695; squares and broken line: sAPP751; triangles and dotted
line: sAPP770. (B) Circular dichroism spectra of sAPP. sAPP was diluted to 0.1 mg/ml in 50 mM Tris, pH 7.4. Circular dichroism was measured
between 260 and 190 nm in 1 nm steps and the appropriate buffer signal was subtracted. Solid line: sAPP695; broken line: sAPP751; dotted line:
sAPP770.
FIGURE 4 Size-exclusion chromatography of purified sAPP. (A) Elution profiles of sAPP isoforms on a GPC-100 Gold column. Elution buffer: 50 mM
Tris, 150 mM NaCl, pH 6.8. Flow rate: 0.3 ml/min. The void volume corresponded to 5.25 min (measured by the elution of plasmid DNA) and the total
column volume corresponded to 11.17 min (measured by the elution of Trp-Gly-Gly). Solid line: sAPP695; broken line: sAPP751; dotted line: sAPP770.
(B) Porath plot (Siegel and Monty, 1966) of reference proteins [from left to right, ovalbumin (45 kDa, 3.05 nm), bovine serum albumin (66 kDa, 3.55 nm),
apoferritin (443 kDa, 6.1 nm), thyroglobulin (669 kDa, 8.5 nm)]. The cubic root of Kd is plotted against the Stokes radius of each protein. Solid line: linear
least-squares fit. Arrow indicates the measured Kd for all three sAPP isoforms.
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detectable dependence of Rg on protein concentration for
one additional diluted sample (Fig. 5 A, inset). This con-
firmed the absence of protein concentration dependence on
the experimental curve used for subsequent data analysis.
Curve-fitting of the experimental data was performed
using the GNOM software package (Svergun and Stuhr-
mann, 1991). Because our samples proved to be non-inter-
acting dilute systems, the extrapolated value of scattering
intensity at zero scattering angle, I(0), was used to obtain an
estimate of the molecular weight of sAPP695 in solution,
using the relation:
MWAPP
I0APP/cAPP
I0Lys/cLys
 MWLys (4)
where cLys and cAPP are, respectively, the concentrations
(mg/ml) of a known reference lysozyme sample and of the
sAPP sample, calculated from the molar sAPP concentra-
tion measured by its absorption band at 280 nm. I(0)Lys is
the zero-angle intensity of the lysozyme sample calculated
from a scattering profile measured under exactly the same
experimental conditions as sAPP695, and MWLys is the
molecular weight of lysozyme. The molecular weight of
sAPP695 thus calculated was 	62 kDa. In addition, the
molecular weight of sAPP695 was also calculated from
SAXS data using the scattering intensity of water as a
reference, as described by Orthaber et al. (2000). Using this
method, sAPP695 was determined to be 	65 kDa. Consid-
ering the independent nature of the two methods used for
determination of the molecular weight of sAPP695 (i.e.,
lysozyme versus water as references), the two molecular
weight estimates are in excellent agreement. These values
are also in good agreement with the calculated polypeptide
mass of sAPP695 (69 kDa) plus the invariant N-glycan
mass of 2 kDa and some contribution from phosphorylation,
sulfation, and O-glycosylation (Weidemann et al., 1989).
Calculation of the molecular mass of pure sAPP695 from
its relative mobility in SDS-PAGE yielded an estimate of 75
kDa (Fig. 1 A, lane 4), which is known to be somewhat
higher than the actual molecular weight (Bush et al., 1994).
The most important conclusion from the molecular weight
estimate is that sAPP695 is undoubtedly a monomer in
solution even at 2.6 mg/ml. Furthermore, the volume of the
sAPP695 particle was calculated as 81,300 Å3. This is 5.9
times the volume of the N-terminal fragment (Rossjohn et
al., 1999), as calculated from the crystal data including a 3
Å water layer (Svergun et al., 1995). As the polypeptide
molecular mass of sAPP695 is 5.7 times the mass of the
N-terminal fragment, the close proportionality between mo-
lecular volume and mass confirms the validity of the data
treatment used and lends further support to the conclusion
that sAPP695 is monomeric in solution.
The value of the radius of gyration of sAPP695 obtained
from the GNOM fit (Fig. 5 A) was 37.9
 0.8 Å. This value
is in good agreement with the value obtained using the
Guinier approximation. The pair-distance distribution func-
FIGURE 5 (A) Small-angle x-ray scattering data and GNOM curve-fitting for a 2.6 mg/ml sAPP695 solution in 50 mM Tris-Cl, pH 7.4. Points and error
bars: experimental data. Solid line: GNOM smeared fit. Broken line: GNOM desmeared fit. Inset: Guinier diagram of SAXS data. Upper line: 2.6 mg/ml
sAPP695. Lower line: 	1:2 dilution. Linear fits of data in the validity region of Guinier’s law (Rg  q  1) yield Rg estimates of 34.8 Å (2.6 mg/ml) and
35 Å (1:2 dilution), showing that concentration-dependent effects do not influence the Rg. (B) Pair-distance distribution function for sAPP695. Solid line:
calculated from the desmeared GNOM fit shown in panel A. Error bars: propagated from experimental error.
3518 Gralle et al.
Biophysical Journal 83(6) 3513–3524
tion P(r), shown in Fig. 5 B, was calculated from the
GNOM fitted data. This curve provided information on
another important structural parameter of sAPP695: the
maximum dimension Dmax  130 Å, determined from the
value of r for which the function P(r) drops to zero. The
ratio of the radius of gyration to the maximum dimension
indicates an elongated shape for sAPP695 in solution. This
is also indicated by the shape of the P(r) function, typical of
an anisometric particle (Glatter and Kratky, 1982).
The information content of a SAXS scattering curve is
limited by the number of Shannon channels, Ns  Dmax
(qmax  qmin)/ (Svergun, 1999). For our measurements on
sAPP695, Ns  12. The relatively low protein concentra-
tion we have used (2.6 mg/ml, equivalent to 41.6 M
sAPP695) leads to lower precision at high q values. To
assess the reliability of the analysis of SAXS data, we
performed control measurements for lysozyme as a standard
protein under exactly the same conditions utilized for sAPP.
Analysis of such data yielded Rg and Dmax values of 14.4 

0.3 Å and 40 
 5 Å, respectively, for lysozyme (data not
shown). These values are in excellent agreement with the
well-known dimensions of lysozyme, indicating the reliabil-
ity of our measurements and methods of analysis.
To obtain a structural model for sAPP in solution, a
model-independent calculation based on spherical harmon-
ics was performed using the program SASHA (Svergun et
al., 1996). In this calculation, it is assumed that the scatter-
ing is caused by globular, homogeneous molecules, and that
the molecular envelope function can be approximated by a
series of spherical harmonics (Stuhrmann, 1970). The res-
olution is determined by the maximum number of harmon-
ics used. A rough approximation to the molecular envelope
was initially obtained by fitting the q region between
0.02043 Å1 and 0.12 Å1 (	4 Shannon channels). The 3D
shape obtained for this low-resolution initial model (not
shown) corresponded to an elongated particle, confirming
the information provided by the P(r) function. No specific
symmetry could be detected from this calculation. The next
step for determination of the 3D structure was shape resto-
ration using finite elements (bead models), without symme-
try constraints, and simulated annealing optimization. This
was performed using the whole range of q measured (12
Shannon channels) and the program DAMMIN (Svergun,
1999) in slow mode, to improve convergence of the simu-
lated annealing procedure to reach a global minimum. Fig.
6 shows the best superimposition (Kozin and Svergun,
2001) of six models obtained from independent calcula-
tions. An asymmetric molecular shape was obtained in the
analysis. Some parts of the structure agree closely in all six
calculations, while other parts are less well-defined. Stokes
FIGURE 6 (A–C) Six superimposed bead model representations of the structural models of sAPP695 calculated using DAMMIN. Panels B and C are
rotated by 90° around the y and z axis, respectively. The intensity of color indicates the degree of coincidence between the six models. For comparison,
the crystal structure of the N-terminal domain of APP (Rossjohn et al., 1999, 1MWP.PDB) is shown in the same scale as panels A–C.
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radii were also calculated for the six models of sAPP695
mentioned above. The calculations were performed using
HYDRO (Garcia de la Torre, 1999), yielding a Stokes
radius of 38.5 
 0.1 Å.
DISCUSSION
This study presents, for the first time, a structural model of
the extracellular domain of the human amyloid precursor
protein in aqueous solution. The secreted extracellular do-
main of APP (sAPP) shows various biological activities in
vivo. On the one hand, sAPP promotes cell growth (Saitoh
et al., 1989) and adhesion (Breen et al., 1991), protection
from excitotoxicity (Mattson et al., 1993), increase in syn-
aptic density (Roch et al., 1994), and memory consolidation
(Meziane et al., 1998). On the other hand, sAPP also acti-
vates microglia (Barger and Harmon, 1997) and leads to
neuronal damage (Barger and Basile, 2001). It is thought
that, as part of the integral transmembrane APP, its extra-
cellular domain mediates similar roles and also stimulates
neurite outgrowth (Qiu et al., 1995). Furthermore, sAPP
reduces Cu(II) to Cu(I) in vitro (Multhaup et al., 1996) and
initiates a Fenton reaction (Multhaup et al., 1998), suggest-
ing a possible role in free radical metabolism. Obtaining a
structural model for sAPP and APP may represent an im-
portant step toward elucidating the molecular basis of in-
teraction with different biological ligands, leading to the
variety of biological activities exhibited by this protein.
SAXS results indicated that sAPP is monomeric in
solution. Interestingly, however, size-exclusion chromatog-
raphy data indicated that the Stokes radius of sAPP was
significantly higher than that expected for a monomer of the
molecular weight of APP (Table 1), suggesting that full-
length sAPP is not a compact spherical molecule. There-
fore, we conclude that sAPP exists predominantly as an
extended monomer in solution under physiological condi-
tions. Comparison of the available crystal structure of the
N-terminal domain of APP with the structural model of
full-length sAPP695 derived from SAXS data (Fig. 6)
shows the anisometry of the structure of sAPP695. As the
Stokes radii of the three sAPP isoforms are the same
within experimental error (Fig. 4), it seems probable that
sAPP751 and sAPP770 are similarly anisometric. Indepen-
dent of the detailed final shape of the structural model, the
anisometry of sAPP is evident from a comparison of the
radius of gyration and the maximum dimension obtained for
sAPP695 (Table 1). Although protein glycosylation is ex-
pected to result in a small increase in particle size, the large
discrepancy between the measured rg value of 38 Å and
Dmax of 130 Å, and the dimensions predicted for sAPP695
according to a spherical model (Table 1), must be due to a
highly non-spherical shape of sAPP.
The extended shape of monomeric sAPP in solution
could result from an elongated rigid structure or from a
flexible structure, with disordered segments connecting or-
dered domains, such as the N-terminal one (Luzzati et al.,
1961). Thus, the model derived by spherical harmonics and
finite element analysis (Fig. 6) could either depict a rigid
molecular shape or the ensemble average of conformation-
ally flexible molecules.
Circular dichroism data analysis supports the notion that
30% of the amino acid residues of APP do not participate
in standard secondary structure elements in the protein (Fig.
3 B). One possible reason for this may be the existence of
disordered regions in sAPP. Indeed, analysis of the primary
sequence of sAPP suggests that it could contain disordered
segments. A stretch of amino acid residues from 190 to 264
[indicated as (DE)n in Fig. 1) is strongly negative, with 56%
of the residues consisting of Glu and Asp and up to eight
contiguous acidic amino acid residues. This region would
be difficult to accommodate in an ordered, folded structure.
This is one of the two regions without strong homology
between APP and the APP-like proteins (APLPs) (Fig. 7;
Wasco et al., 1992, 1993). The consensus of the secondary
structure prediction algorithms we have used predicts a low
content of -helix and -sheet in this part of APP (Fig. 7).
Second, the two extracellular phosphorylation sites of APP
lie in the same region (Caporaso et al., 1992), contributing
additional negative charges. The saccharide side chains of
APP are also negatively charged (Weidemann et al., 1989)
and may therefore exert repulsive interactions upon each
other and upon negatively charged regions of the polypep-
tide chain. Finally, a stretch of amino acid residues that lies
upstream from the amyloidogenic A sequence (residues
582 to 663 in APP770; labeled RC in Fig. 1) is predicted by
10 different secondary structure prediction algorithms to be
devoid of helical or extended sheet structure (Fig. 7). This is
the second large region of APP without homology to the
otherwise very similar APP-like proteins (APLPs) (see Fig.
7) and therefore may correspond to an important domain for
biological functions specifically carried out by APP (see
below).
TABLE 1 Dimensional data for sAPP695
Source Rg (Å) RS (Å) Dmax (Å)
Gel-filtration data — 51 —
SAXS data (Guinier) 35 — —
SAXS data (whole range) 38* 39† 130*
Spherical model 24‡ 31§ 62§
Comparison of radius of gyration (Rg), Stokes radius (RS), and maximum
dimension (Dmax) determined from experimental data or assuming a spher-
ical model.
*Calculated from the GNOM fit of the SAXS data (Svergun and Stuhr-
mann, 1991).
†Calculated from the DAMMIN model (Svergun, 1999) using HYDRO
(Garcia de la Torre, 1994).
‡Calculated as Rg  2.9  n
1.3, with n (number of amino acid residues) 
595 for sAPP695 (Gast et al., 1995).
§Calculated using RS  (5/3)
1/2  Rg (Luzzati et al., 1961) and Dmax  2 
RS for spherical molecules.
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Although a stabilizing function for Zn2 ions has been
hypothesized (Bush et al., 1994), it is remarkable that the
polypeptide crystallized from a solution of APP1-324
(Rossjohn et al., 1999) appeared to contain neither the Cu2
nor the Zn2 binding domains (indicated as CuBD and
ZnBD in Fig. 1). This may be analogous to the flexibility of
the Cu2 binding site present in the octarepeat Cu2-bind-
ing region of the prion protein (Aronoff-Spencer et al.,
2000), which was not resolved in nuclear magnetic reso-
nance structures of the whole prion protein (Donne et al.,
1997). In addition to the possible presence of flexible seg-
ments in its extracellular domain, the short cytoplasmic
domain of APP has been shown by nuclear magnetic reso-
nance studies to be highly mobile (Ramelot et al., 2000). It
was hypothesized that this mobility enables APP to bind, at
overlapping binding sites, different intracellular ligands
with different binding requirements.
Recently, it has become clear that partially unstructured
proteins are by no means an exception in the human ge-
nome. An unordered structure in the absence of ligand may
enable a protein domain to recognize its ligand or multiple
ligands with high specificity (Wright and Dyson, 1999). The
various extracellular matrix components that bind to sAPP
(Narindrasorasak et al., 1992; Beher et al., 1996; Mok et al.,
1997; Ohsawa et al., 2001) may well bind alternately to
neighboring binding sites.
Another consideration pertinent to the possible flexibility
of sAPP is in connection with the lability of this protein in
vivo (Koo et al., 1996). The extremely potent memory-
affecting (Roch et al., 1994), radical-generating (Multhaup
et al., 1998), and cytotoxic (Barger and Basile, 2001) ac-
tivities of sAPP certainly require precise spatiotemporal
mechanisms of regulation (Lyckman et al., 1998) that may
involve inhibition and/or degradation of APP. It may be
easier to rapidly degrade a flexible protein. Once again, the
flexible cytoplasmic domain of APP provides an interesting
analogy. After cleavage by -secretase, it is released from
the plasma membrane into the cytoplasm and is rapidly
degraded when not bound to a signal transduction protein
(Kimberly et al., 2001). Finally, a flexible structure of sAPP
might explain the difficulties in finding the sAPP “receptor”
and in elucidating the complete APP signal transduction
chain from the extracellular signal to the nucleus (Gao and
Pimplikar, 2001; Sisodia and Gallagher, 1998). Our pro-
posed model for the structure of sAPP thus serves as a first
step toward elucidation of the transient and alternate mo-
lecular interactions of APP with different biological ligands
in the extracellular medium.
A further perspective is provided by the fact that a large
part of the sequence of sAPP is shared by its homologs
APLP1 and APLP2. APP, APLP1, and APLP2 are believed
to have similar roles in neurite outgrowth and synapse
development (Cappai et al., 1999; Heber et al., 2000) and
APP-knockout mice are viable as long as they have a
functional APLP1 or APLP2 gene (Heber et al., 2000),
probably reflecting the conservation of most domains
among all three proteins. However, several neurological
deficits and morphological abnormalities have been de-
scribed in APP-knockout mice (Heber et al., 2000). This
suggests there are functions of APP that cannot be compen-
sated by its homologs, and it would appear reasonable to
search for their structural correlates in APP-specific regions,
such as the random coil region and the amyloidogenic
sequence (Figs. 1 and 7). Surprisingly, APLP2, which
shares 50% sequence identity and 69% sequence homology
with APP751 (Fig. 7), has been shown to interact with a
major histocompatibility complex class I molecule in the
endoplasmic reticulum (Sester et al., 2000) and to be iden-
tical with a DNA-binding protein (Rassoulzadegan et al.,
1998). It is challenging to explain how proteins of the same
family and with such high sequence homology can interact
with ligands of such diverse natures and in such varied
FIGURE 7 Secondary structure prediction and sequence conservation for APP protein family members. The consensus of the secondary structure
prediction algorithms (Combet et al., 2000 is shown color-coded for the sequence of APP751 (top diagram) and its nearest homolog, APLP2763 (bottom
diagram). Blue bars: -helix; red bars: -sheet; yellow bars: no secondary structure (random coil); gray bars: no consensus. The difference in sequence
length is mainly due to a longer signal peptide in APLP2. Amino acid sequence homology between APP and APLP2 (middle diagram) is shown as a black
bar for each identical or strongly similar residue, according to the CLUSTAL W algorithm implemented in NPS@ (Combet et al., 2000). The sequence
marked RC in Fig. 1 corresponds to residues 563 to 644 in APP751 (this figure).
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environments, unless a significant degree of structural plas-
ticity is taken into account.
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